BAO PHARMA-B (02659) has announced that, in accordance with the relevant regulations of the Shanghai Stock Exchange and the Shenzhen Stock Exchange for the Stock Connect programs, the company's H-shares listed on the Hong Kong Stock Exchange will be included as eligible securities under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, collectively known as the "Southbound Stock Connect." This inclusion will take effect from March 9, 2026. This move signifies the company's formal entry into the view of mainland investors and is expected to bring dual opportunities through capital access and value reassessment.

The Southbound Stock Connect serves as a vital channel linking the mainland and Hong Kong capital markets. Inclusion in the program requires meeting multiple criteria, including market capitalization and liquidity standards. For BAO PHARMA-B, being included is set to significantly enhance the market liquidity of its shares. As incremental southbound capital interacts deeply with the company's "innovative R&D + biomanufacturing" technological strategy, it will help solidify the company's growth rationale and development prospects within the healthcare industry. This further demonstrates to the capital markets its structural value as a new-generation platform-based Biopharma company.

BAO PHARMA-B is poised for major catalysts in commercial transformation, with several core products potentially contributing significant revenue this year. Xiniu Securities pointed out that KJ017 (recombinant human hyaluronidase) is expected to receive New Drug Application (NDA) approval in 2026. Currently, recombinant human hyaluronidase is not marketed in China as a monotherapy; its launch could unlock substantial commercial potential and accelerate the company's commercialization process. Additionally, the company's self-developed long-acting recombinant human follicle-stimulating hormone (FSH-CTP) injection, Sheng Nuowa® (SJ02), has already received market approval. BAO PHARMA-B has entered into an exclusive sales agreement for Greater China with Anke Biotechnology (300009.SZ), successfully achieving commercial deployment.

Long-term, leveraging its leading capabilities in chassis cell construction, a stable commercial production system, and an experienced R&D team, BAO PHARMA-B possesses strong momentum in its commercial transformation pathway. With the continued advancement of its core product pipeline, the company is expected to achieve growth in both capital value and operational performance, continually highlighting its investment value.